9 publications
| Name | Date | Type | Actions |
|---|---|---|---|
H1 2021 results H1 2021 results |
29/07/2021 | Half Year Report | |
2021 first half results 2021 Half year results |
29/07/2021 | Public releases | |
2020 annual results 2020 sales: €427.5m (up 8.0% as reported)
EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m
|
01/04/2021 | Public releases | |
H1 results presentation Slideshow - July 27, 2017 |
27/07/2017 | Half Year Report | |
2016 Annual Results Présentation analystes & investisseurs - 23 mars 2017 |
23/03/2017 | Annual Report | |
All key financial indicators up in 2016 At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. |
22/03/2017 | Public releases | |
Reference products up 6.1% like-for-like in H1 net income group share up 6.5% to €14.4 million At its meeting on July 26, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first half of 2017. |
27/07/2017 | Public releases | |
Vetoquinol acquires Equity Stake in Plant Advanced Technologies PAT Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT. |
13/11/2017 | Public releases | |
Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health. |
08/02/2021 | press release excluding results |